522 related articles for article (PubMed ID: 17308104)
21. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
[TBL] [Abstract][Full Text] [Related]
22. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
23. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells.
Zaidman BZ; Wasser SP; Nevo E; Mahajna J
Int J Oncol; 2007 Oct; 31(4):959-67. PubMed ID: 17786330
[TBL] [Abstract][Full Text] [Related]
25. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
26. Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.
Kampa M; Theodoropoulou K; Mavromati F; Pelekanou V; Notas G; Lagoudaki ED; Nifli AP; Morel-Salmi C; Stathopoulos EN; Vercauteren J; Castanas E
J Pharmacol Exp Ther; 2011 Apr; 337(1):24-32. PubMed ID: 21205921
[TBL] [Abstract][Full Text] [Related]
27. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Thorpe JA; Christian PA; Schwarze SR
Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
32. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
[TBL] [Abstract][Full Text] [Related]
33. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
34. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
Kim J; Park H; Im JY; Choi WS; Kim HS
Anticancer Res; 2007; 27(5A):3285-92. PubMed ID: 17970072
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
36. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
37. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.
Zoubeidi A; Zardan A; Beraldi E; Fazli L; Sowery R; Rennie P; Nelson C; Gleave M
Cancer Res; 2007 Nov; 67(21):10455-65. PubMed ID: 17974989
[TBL] [Abstract][Full Text] [Related]
38. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.
You Z; Shi XB; DuRaine G; Haudenschild D; Tepper CG; Lo SH; Gandour-Edwards R; de Vere White RW; Reddi AH
Cancer Res; 2006 Jan; 66(1):175-83. PubMed ID: 16397230
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis of human prostate androgen-dependent and -independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) 18.
Hostanska K; Nisslein T; Freudenstein J; Reichling J; Saller R
Anticancer Res; 2005; 25(1A):139-47. PubMed ID: 15816531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
